Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for unresectable colorectal peritoneal metastases
2022-002134-14Phase 2Active
- Sponsor
- Catharina Ziekenhuis
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in colorectal cancer (CRC), sponsored by Catharina Ziekenhuis. Primary endpoint: Overall survival. Started Jul 2022; status: active.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-002134-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002134-14.